10250-64-3

Basic information

• Product Name: 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLIC ACID
• Synonyms: 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLIC ACID;1-Methyl-3-phenyl-1H-pyrazole-5-carboxylic acid 97%;2-Methyl-5-phenyl-2H-pyrazole-3-carboxylic acid;1-methyl-3-phenyl-1H-pyrazole-5-carboxylic acid(SALTDATA: FREE);5-Carboxy-1-methyl-3-phenyl-1H-pyrazole;1H-Pyrazole-5-carboxylic acid, 1-methyl-3-phenyl-
• CAS NO: 10250-64-3
• Molecular Formula: C₁₁H₁₀N₂O₂
• Molecular Weight: 202.21
• Mol File: 10250-64-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 186 °C
• Boiling Point: 419.6 °C at 760 mmHg
• Flash Point: 207.6 °C
• Appearance: /
• Density: 1.24 g/cm³
• Vapor Pressure: 8.62E-08mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: 2-8°C
• PKA: 2.97±0.25(Predicted)
• CAS DataBase Reference: 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLIC ACID(10250-64-3)
• EPA Substance Registry System: 1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLIC ACID(10250-64-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• WGK Germany: 3
• Hazardous Substances Data: 10250-64-3(Hazardous Substances Data)

Usage

General Description

1-METHYL-3-PHENYL-1H-PYRAZOLE-5-CARBOXYLIC ACID is an organic compound with a pyrazole ring and a carboxylic acid functional group. It is a white powder with a molecular formula of C11H10N2O2. This chemical is commonly used in pharmaceutical research as a building block for the synthesis of various biologically active compounds and drug candidates. Its molecular structure and properties make it a versatile intermediate for the development of new drugs targeting various biological pathways. Additionally, it has potential applications in the field of medicinal chemistry and agrochemicals.

InChI:InChI=1/C11H10N2O2/c1-13-10(11(14)15)7-9(12-13)8-5-3-2-4-6-8/h2-7H,1H3,(H,14,15)

Upstream product

• 10250-62-1 1-Methyl-3-phenylpyrazol-5-carbonsaeure-methylester 
• 56426-35-8 methyl 5-phenyl-1H-pyrazole-3-carboxylate 
• 10250-63-2 1-methyl-3-phenyl-1H-prazole-5-carboxylic acid ethyl ester 
• 89088-56-2 methyl 1-methyl-3-aminopyrazole-5-carboxylate 
• 98-80-6 phenylboronic acid 
• 6296-54-4 ethyl 2,4-dioxo-4-phenylbutyrate 
• 98-86-2 acetophenone 
• 20577-73-5 methyl 4-phenyl-2,4-dioxobutanoate 

Downstream Products

• 1104267-88-0 1-methyl-3-phenyl-N-[(1-pyridin-3-ylcyclohexyl)methyl]-1H-pyrazole-5-carboxamide 
• 1207726-20-2 C₂₅H₂₃N₃O₃ 
• 1415757-44-6 (R)-2-{3-fluoro-4-[(2-methyl-5-phenyl-2H-pyrazole-3-carbonyl)-amino]-phenyl}-morpholine-4-carboxylic acid tert-butyl ester 
• 1558041-33-0 N-((3R,5S)-1-(benzofuran-3-carbonyl)-5-(ethylcarbamoyl)pyrrolidin-3-yl)-1-methyl-3-phenyl-1H-pyrazole-5-carboxamide 
• 1227681-73-3 C₂₂H₂₁N₅O₃ 
• 1207725-94-7 C₂₁H₁₉N₅O₃ 
• 1569316-66-0 C₂₂H₂₁N₅O₃ 
• 1569316-89-7 C₂₁H₁₉N₅O₃ 

Relevant articles and documents

FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR

The present invention discloses a five-membered heterocyclic amide WNT pathway inhibitor, which belongs to a compound that regulates the activity of a Wnt signaling pathway, and provides a method for preparing such a compound, and the use of such a compound in preparing a medicament that antagonizes the Wnt signaling pathway. The five-membered heterocyclic amide WNT pathway inhibitor provided by the invention has a remarkable anti-tumor activity based on a target-based rational drug design of, and can be used for the development of a new generation of Wnt pathway inhibitors, and has a great clinical application value and considerable market potential.

HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR

A novel heterocyclic compound or a salt thereof useful for selectively inhibiting the degradation of p27Kip1 is provided. The compound or the salt thereof is represented by the following formula (1): wherein A represents an alkyl group, a cycloalkyl group, an aryl group or a heterocyclic group, the group A may have a substituent; the ring B represents a 5- to 8-membered monocyclic heterocyclic ring or a condensed ring containing the monocyclic heterocyclic ring, the ring B may have a substituent; the ring C represents an aromatic ring, the ring C may have a substituent; L represents a linker comprising a main chain having 3 to 5 atoms selected from the group consisting of a carbon atom, a nitrogen atom, an oxygen atom and a sulfur atom, wherein at least one atom in the main chain is a hetero atom selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom, the linker L may have a substituent; and n is 0 or 1.

AMIDE COMPOUNDS

The present invention provides compounds represented by the formula (Ia) the formula (Ib) the formula (Ic) and the formula (Id) wherein each symbol is as defined in the specification. According to the present invention, these compounds have a DGAT inhibit